IDEXX Laboratories, Inc. IDXX

519.26 5.87 1.14% as of 25 Sep
Market cap
$40.2B
P/E
36.2×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

IDEXX Laboratories, Inc. (IDXX) Return on equity

IDEXX Laboratories, Inc.'s return on equity over the twelve months to 30 June 2026 was 74.2%, up 8.0 percentage points from fiscal 2025 (66.2%). Over the past ten years it has ranged from −1,195.5% (fiscal 2018) to 1,143.5% (fiscal 2015); the current reading is higher than 45% of that period. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −32.0%.

Return on equity, annual

Annual

Period Return on equity Change (points)
FY2025 66.2% 8.54
FY2024 57.7% (23.08)
FY2023 80.7% (23.84)
FY2022 104.6% (8.04)
FY2021 112.6% (30.92)
FY2020 143.5% (363.86)
FY2019 507.4% 1,702.90
FY2018 −1,195.5% (870.74)
FY2017 −324.8% (93.71)
FY2016 −231.1% (1,374.58)

Against its own ten years

Low −1,195.5% High 1,143.5%
Ten-year median 80.7%
Current reading's percentile 45

Return on equity against peers

Company Return on equity
GH Guardant Health, Inc. compare 171.6%
IDXX IDEXX Laboratories, Inc. 74.2%
ILMN Illumina, Inc. compare 32.4%
IQV IQVIA Holdings Inc. compare 22.8%
A Agilent Technologies, Inc. compare 21.0%
DGX Quest Diagnostics Incorporated compare 14.0%
WAT Waters Corporation compare 1.92%
NTRA Natera, Inc. compare −12.5%
MTD Mettler-Toledo International, Inc. compare −736.4%
Diagnostics & Research industry median −2.92%
Healthcare sector median −32.0%
Market median 1.76%

What Return on equity is

ROE shows how much profit a company earns for its shareholders on the equity they have in the business.

Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)

The full definition of Return on equity →

More on IDXX